The co‐occurrence of early onset Parkinson disease and 22q11.2 deletion syndrome
2009; Wiley; Volume: 149A; Issue: 3 Linguagem: Inglês
10.1002/ajmg.a.32650
ISSN1552-4833
AutoresChristina Zaleski, Anne S. Bassett, Karen Tam, Andrea Shugar, Eva W.C. Chow, Elizabeth McPherson,
Tópico(s)Cardiac Fibrosis and Remodeling
ResumoAmerican Journal of Medical Genetics Part AVolume 149A, Issue 3 p. 525-528 Research Letter The co-occurrence of early onset Parkinson disease and 22q11.2 deletion syndrome† Christina Zaleski, Christina Zaleski Department of Medical Genetic Services, Marshfield Clinic, Marshfield, WisconsinSearch for more papers by this authorAnne S. Bassett, Anne S. Bassett Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada Department of Psychiatry, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this authorKaren Tam, Karen Tam Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, CanadaSearch for more papers by this authorAndrea L. Shugar, Andrea L. Shugar Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, CanadaSearch for more papers by this authorEva W.C. Chow, Eva W.C. Chow Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada Department of Psychiatry, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this authorElizabeth McPherson, Corresponding Author Elizabeth McPherson [email protected] Department of Medical Genetic Services, Marshfield Clinic, Marshfield, WisconsinDepartment of Medical Genetic Services, Marshfield Clinic, 1000 North Oak Avenue 1A4, Marshfield, WI 54449.Search for more papers by this author Christina Zaleski, Christina Zaleski Department of Medical Genetic Services, Marshfield Clinic, Marshfield, WisconsinSearch for more papers by this authorAnne S. Bassett, Anne S. Bassett Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada Department of Psychiatry, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this authorKaren Tam, Karen Tam Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, CanadaSearch for more papers by this authorAndrea L. Shugar, Andrea L. Shugar Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, CanadaSearch for more papers by this authorEva W.C. Chow, Eva W.C. Chow Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada Department of Psychiatry, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this authorElizabeth McPherson, Corresponding Author Elizabeth McPherson [email protected] Department of Medical Genetic Services, Marshfield Clinic, Marshfield, WisconsinDepartment of Medical Genetic Services, Marshfield Clinic, 1000 North Oak Avenue 1A4, Marshfield, WI 54449.Search for more papers by this author First published: 10 February 2009 https://doi.org/10.1002/ajmg.a.32650Citations: 39 † How to cite this article: Zaleski C, Bassett AS, Tam K, Shugar AL, Chow EC, McPherson E. 2009. The co-occurrence of early onset Parkinson disease and 22q11.2 deletion syndrome. Am J Med Genet Part A 149A:525–528. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES Bassett AS, Chow EW. 2008. Schizophrenia and 22q11.2 deletion syndrome. Curr Psychiatry Rep 10: 148–157. 10.1007/s11920-008-0026-1 PubMedGoogle Scholar Bassett AS, Chow EW, Husted J, Weksberg R, Caluseriu O, Webb GD, Gatzoulis MA. 2005. Clinical features of 78 adults with 22q11 deletion syndrome. Am J Med Genet Part A 138A: 307–313. 10.1002/ajmg.a.30984 Web of Science®Google Scholar Bassett AS, Caluseriu O, Weksberg R, Young D, Chow EW. 2007. Catechol-O-methyl transferase and expression of schizophrenia in 73 adults with 22q11 deletion syndrome. Biol Psychiatry 61: 1135–1140. 10.1016/j.biopsych.2006.07.038 CASPubMedWeb of Science®Google Scholar Bialecka M, Drozdzik M, Klodowska-Duda G, Honczarenko K, Gawronska-Szklarz B, Opala G, Stankiewicz J. 2004. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease. Acta Neurol Scand 110: 260–266. 10.1111/j.1600-0404.2004.00315.x CASPubMedWeb of Science®Google Scholar Bialecka M, Drozdzik M, Honczarenko K, Gawronska-Szklarz B, Stankiewicz J, Dabrowska E, Kubisiak M, Klodowska-Duda G, Opala G. 2005. Catechol-O-methyltransferase and monoamine oxidase B genes and susceptibility to sporadic Parkinson's disease in a Polish population. Eur Neurol 53: 68–73. 10.1159/000084302 CASPubMedWeb of Science®Google Scholar Bodis-Wollner I. 2003. Neuropsychological and perceptual defects in Parkinson's disease. Parkinsonism Relat Disord 9: S83–S89. 10.1016/S1353-8020(03)00022-1 PubMedWeb of Science®Google Scholar Botto LD, May K, Fernhoff PM, Correa A, Coleman K, Rasmussen SA, Merritt RK, O'Leary LA, Wong LY, Elixson EM, Mahle WT, Campbell RM. 2003. A population-based study of the 22q11.2 deletion: Phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 112: 101–107. 10.1542/peds.112.1.101 PubMedWeb of Science®Google Scholar Chow EW, Watson M, Young DA, Bassett AS. 2006. Neurocognitive profile in 22q11 deletion syndrome and schizophrenia. Schizophr Res 87: 270–278. 10.1016/j.schres.2006.04.007 PubMedWeb of Science®Google Scholar Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA. 2002. Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol 55: 25–31. 10.1016/S0895-4356(01)00425-5 PubMedWeb of Science®Google Scholar Foltynie T, Goldberg TE, Lewis SG, Blackwell AD, Kolachana BS, Weinberger DR, Robbins TW, Barker RA. 2004. Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. Mov Disord 19: 885–891. 10.1002/mds.20118 CASPubMedWeb of Science®Google Scholar Ishihara L, Brayne C. 2006. What is the evidence for a premorbid parkinsonian personality: A systematic review. Mov Disord 21: 1006–1072. 10.1002/mds.20980 Web of Science®Google Scholar Kaasinen V, Nurmi E, Bruck A, Eskola O, Bergman J, Solin O, Rinne JO. 2001. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: Sex differences in the prefrontal cortex. Brain 124: 1125–1130. 10.1093/brain/124.6.1125 CASPubMedWeb of Science®Google Scholar Krahn LE, Maraganore DM, Michels VV. 1998. Childhood-onset schizophrenia associated with parkinsonism in a patient with a microdeletion of chromosome 22. Mayo Clin Proc 73: 956–959. 10.4065/73.10.956 CASPubMedWeb of Science®Google Scholar Lynch DR, McDonald-McGinn DM, Zackei EH, Emanuel BS, Driscoll DA, Whitaker LA, Fishbeck KH. 1995. Cerebellar atrophy in a patient with velocardiofacial syndrome. J Med Genet 32: 561–563. 10.1136/jmg.32.7.561 CASPubMedWeb of Science®Google Scholar Oskarsdottir S, Vujic M, Fasth A. 2004. Incidence and prevalence of the 22q11 deletion syndrome: A population-based study in Western Sweden. Arch Dis Child 89: 148–151. 10.1136/adc.2003.026880 CASPubMedWeb of Science®Google Scholar Pycock CJ, Carter CJ, Kerwin RW. 1980. Effect of 6-hydroxydopamine lesions of the medial prefrontal cortex on neurotransmitter systems in subcortical sites in the rat. J Neurochem 34: 91–99. 10.1111/j.1471-4159.1980.tb04625.x CASPubMedWeb of Science®Google Scholar Rakshi JS, Uema T, Ito K, Bailey DL, Morrish PK, Ashburner J, Dagher A, Jenkins IH, Friston KJ, Brooks DJ. 1999. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. Brain 122: 1637–1650. PubMedWeb of Science®Google Scholar Shprintzen R. 2005. Velo-cardio-facial syndrome. In: SB Cassidy, JE Allanson, editors. Management of genetic syndromes, 2nd edition. New York: Wiley-Liss. pp 615–631. 10.1002/0471695998.mgs051 Google Scholar Taba P, Asser T. 2002. Prevalence of Parkinson's disease in Estonia. Acta Neurol Scand 106: 276–281. 10.1034/j.1600-0404.2002.01286.x CASPubMedWeb of Science®Google Scholar Tam K, Bassett A, Chow E. 2004. The co-occurrence of 22q11 deletion syndrome and Parkinson disease: A new neurological feature? American Society of Human Genetics Meeting, Toronto, 2004. Available at: http://www.ashg.org/genetics/abstracts/abs04/f769.htm (accessed August 7, 2008). Google Scholar Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. 2003. Incidence of Parkinson's disease: Variation by age, gender, and race/ethnicity. Am J Epidemiol 157: 1015–1022. 10.1093/aje/kwg068 PubMedWeb of Science®Google Scholar Williams-Gray CH, Hampshire A, Robbins TW, Owen AM, Barker RA. 2007. Catechol O-methyltransferase val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci 27: 4832–4838. 10.1523/JNEUROSCI.0774-07.2007 CASPubMedWeb of Science®Google Scholar Wilson DI, Cross IE, Wren C, Scambler PJ, Burn J, Goodship J. 1994. Minimum prevalence of chromosome 22q11 deletions. Am J Hum Genet 55: A169. Google Scholar Citing Literature Volume149A, Issue3March 2009Pages 525-528 ReferencesRelatedInformation
Referência(s)